Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.62 +3.9%	$20.78	$16.10 ▼ $41.94	$3.36B	0.78	3.28 million shs	2.00 million shs
LNTH Lantheus	$59.16 +5.4%	$71.87	$47.25 ▼ $118.21	$3.82B	0.14	2.33 million shs	3.65 million shs
MLTX MoonLake Immunotherapeutics	$54.17 +0.1%	$50.28	$31.42 ▼ $58.26	$3.48B	1.27	466,175 shs	435,402 shs
ORIC Oric Pharmaceuticals	$9.69 +1.9%	$10.30	$3.90 ▼ $14.67	$923.64M	1.69	1.32 million shs	353,405 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-0.37%	0.00%	+37.86%	+49.49%	-31.76%
LNTH Lantheus	+1.80%	+4.37%	-21.55%	-24.90%	-42.97%
MLTX MoonLake Immunotherapeutics	+2.81%	-2.71%	+1.06%	+40.59%	+9.40%
ORIC Oric Pharmaceuticals	-0.94%	-3.26%	-14.01%	+59.83%	-3.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.513 of 5 stars	4.3	1.0	4.4	3.3	2.5	0.6
LNTH Lantheus	4.7495 of 5 stars	4.4	1.0	4.2	3.3	2.5	1.9
MLTX MoonLake Immunotherapeutics	1.5991 of 5 stars	3.4	1.0	0.0	1.0	2.5	0.0
ORIC Oric Pharmaceuticals	4.7276 of 5 stars	4.5	3.0	4.4	2.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	23.53% Upside
LNTH Lantheus	2.71	Moderate Buy	$105.50	78.33% Upside
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$74.43	37.40% Upside
ORIC Oric Pharmaceuticals	2.90	Moderate Buy	$17.63	81.89% Upside

Current Analyst Ratings Breakdown

Latest ORIC, LNTH, APLS, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ORIC Oric Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
8/14/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $19.00
8/13/2025	ORIC Oric Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/12/2025	ORIC Oric Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/11/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Hold	$111.00 ➝ $63.00
8/7/2025	LNTH Lantheus	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$112.00 ➝ $73.00
8/7/2025	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$120.00 ➝ $70.00
8/6/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $82.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.46	N/A	N/A	$1.24 per share	22.27
LNTH Lantheus	$1.53B	2.62	$7.61 per share	7.77	$17.16 per share	3.45
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$5.57 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.76	15.73	9.38	N/A	17.82%	34.06%	19.10%	11/5/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.78	N/A	N/A	N/A	N/A	-40.98%	-35.81%	11/6/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.89	N/A	N/A	N/A	N/A	-51.75%	-47.09%	N/A

Latest ORIC, LNTH, APLS, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	-$0.47	-$0.01	-$0.47	N/A	N/A
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	$1.57	-$0.08	$1.12	$389.69 million	$378.05 million
8/5/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	-$0.87	-$0.14	-$0.87	N/A	N/A
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
LNTH Lantheus	0.49	4.29	4.07
MLTX MoonLake Immunotherapeutics	0.21	16.65	16.65
ORIC Oric Pharmaceuticals	N/A	16.13	16.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
LNTH Lantheus	99.06%
MLTX MoonLake Immunotherapeutics	93.85%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
LNTH Lantheus	1.50%
MLTX MoonLake Immunotherapeutics	12.02%
ORIC Oric Pharmaceuticals	6.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
LNTH Lantheus	700	67.99 million	66.97 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.23 million	56.51 million	Optionable
ORIC Oric Pharmaceuticals	80	97.12 million	90.50 million	Optionable

ORIC, LNTH, APLS, and MLTX Headlines

Recent News About These Companies

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Short Interest Down 45.0% in July

August 20 at 11:47 AM | marketbeat.com

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief ...

August 19 at 2:42 PM | bakersfield.comB

ORIC Pharmaceuticals: ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

August 19 at 9:41 AM | finanznachrichten.de

ORIC Pharmaceuticals Reports Q2 2025 Financial Results

August 19 at 9:41 AM | msn.com

Oric Pharmaceuticals appoints Kevin Brodbeck CTO

August 19 at 9:41 AM | msn.com

Equities Analysts Offer Predictions for ORIC Q3 Earnings

August 19 at 2:56 AM | marketbeat.com

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

August 18 at 4:05 PM | globenewswire.com

Wedbush Predicts Weaker Earnings for Oric Pharmaceuticals

August 17, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded to Hold at Zacks Research

August 17, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at JPMorgan Chase & Co.

August 17, 2025 | americanbankingnews.com

HC Wainwright Lowers Oric Pharmaceuticals (NASDAQ:ORIC) Price Target to $19.00

August 17, 2025 | americanbankingnews.com

Q3 EPS Estimate for Oric Pharmaceuticals Reduced by Analyst

August 17, 2025 | americanbankingnews.com

JPMorgan Chase & Co. Has Lowered Expectations for Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price

August 16, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Given New $19.00 Price Target at HC Wainwright

August 16, 2025 | marketbeat.com

Oric Pharmaceuticals' (ORIC) Buy Rating Reiterated at Guggenheim

August 15, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Earns "Buy" Rating from Guggenheim

August 15, 2025 | americanbankingnews.com

Oric Pharmaceuticals (NASDAQ:ORIC) Posts Earnings Results, Misses Expectations By $0.01 EPS

August 14, 2025 | marketbeat.com

Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize

August 14, 2025 | pharmexec.comP

Oric lays off 20% of workforce to strengthen focus on clinical-stage cancer drugs

August 13, 2025 | fiercebiotech.comF

Oric Pharmaceuticals Focuses on Lead Clinical Programs

August 12, 2025 | msn.com

Oric Pharmaceuticals reports Q2 EPS (47c), consensus (44c)

August 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ORIC, LNTH, APLS, and MLTX Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.62 +1.04 (+3.91%)

Closing price 04:00 PM Eastern

Extended Trading

$27.54 -0.09 (-0.31%)

As of 06:16 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Lantheus NASDAQ:LNTH

$59.16 +3.02 (+5.38%)

Closing price 04:00 PM Eastern

Extended Trading

$59.08 -0.08 (-0.14%)

As of 07:52 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$54.17 +0.03 (+0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$53.62 -0.55 (-1.02%)

As of 06:06 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Oric Pharmaceuticals NASDAQ:ORIC

$9.69 +0.18 (+1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$9.61 -0.08 (-0.87%)

As of 04:10 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time